Also published in Medical Xpress:
Measuring Mutations in Sperm May Reveal Risk for Autism in Future Children
x hide permanently

Nivolumab + Ipilimumab: Added Benefit in Pleural Mesothelioma With Non-Epithelioid Tumour Histology

Medical Xpress

Photo: CC0 Public Domain

The monoclonal antibodies nivolumab and ipilimumab have already undergone several early benefit assessments in various oncological indications. Since April 2021, the drug combination has also been approved for first-line treatment of unresectable malignant pleural mesothelioma in adults. Therefore, the German Institute for Quality and Efficiency in Health Care (IQWiG) has now investigated whether it offers an added benefit to the patients.

The effect depends on a subgroup characteristic, i.e. "tumor histology": For patients with non-epithelioid mesothelioma, there is an indication of considerable added benefit compared to platinum-based chemotherapy consisting of pemetrexed and cisplatin ...